Cargando…

3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma

SIMPLE SUMMARY: Follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Although huge efforts have been made in the last 10 years, this pathology is still considered as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gava, Fabien, Faria, Carla, Gravelle, Pauline, Valero, Juan G., Dobaño-López, Cèlia, Morin, Renaud, Norlund, Marine, Gomes, Aurélie, Lagarde, Jean-Michel, Rossi, Cédric, Bordenave, Julie, Pieruccioni, Laetitia, Rouquette, Jacques, Matas-Céspedes, Alba, Fournié, Jean-Jacques, Ysebaert, Loïc, Laurent, Camille, Pérez-Galán, Patricia, Bezombes, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036410/
https://www.ncbi.nlm.nih.gov/pubmed/33804934
http://dx.doi.org/10.3390/cancers13071490
_version_ 1783676903594393600
author Gava, Fabien
Faria, Carla
Gravelle, Pauline
Valero, Juan G.
Dobaño-López, Cèlia
Morin, Renaud
Norlund, Marine
Gomes, Aurélie
Lagarde, Jean-Michel
Rossi, Cédric
Bordenave, Julie
Pieruccioni, Laetitia
Rouquette, Jacques
Matas-Céspedes, Alba
Fournié, Jean-Jacques
Ysebaert, Loïc
Laurent, Camille
Pérez-Galán, Patricia
Bezombes, Christine
author_facet Gava, Fabien
Faria, Carla
Gravelle, Pauline
Valero, Juan G.
Dobaño-López, Cèlia
Morin, Renaud
Norlund, Marine
Gomes, Aurélie
Lagarde, Jean-Michel
Rossi, Cédric
Bordenave, Julie
Pieruccioni, Laetitia
Rouquette, Jacques
Matas-Céspedes, Alba
Fournié, Jean-Jacques
Ysebaert, Loïc
Laurent, Camille
Pérez-Galán, Patricia
Bezombes, Christine
author_sort Gava, Fabien
collection PubMed
description SIMPLE SUMMARY: Follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Although huge efforts have been made in the last 10 years, this pathology is still considered as incurable, leaving open the discovery and testing of new therapeutic targets requiring relevant preclinical models. Here, we report a realistic 3D model of t (14;18)-positive B-NHL cell culture (ultra-low attachment (ULA)-multicellular aggregates of lymphoma cells (MALC)), which monitored by state-of-the-art 2D and 3D imaging, allows more robust drug testing. ABSTRACT: Follicular lymphoma (FL) is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Great advances have been made to identify the most relevant targets for precision therapy. However, no relevant models for in vitro studies have been developed or characterized in depth. To this purpose, we generated a 3D cell model from t(14;18)-positive B-NHL cell lines cultured in ultra-low attachment 96-well plates. Morphological features and cell growth behavior were evaluated by classical microscopy (2D imaging) and response to treatment with different drugs was evaluated by a high-content analysis system to determine the robustness of the model. We show that the ultra-low attachment (ULA) method allows the development of regular, spherical and viable ULA-multicellular aggregates of lymphoma cells (MALC). However, discrepancies in the results obtained after 2D imaging analyses on drug-treated ULA-MALC prompted us to develop 3D imaging and specific analyses. We show by using light sheet microscopy and specifically developed 3D imaging algorithms that 3D imaging and dedicated analyses are necessary to characterize morphological properties of 3D models and drug effects. This study proposes a new method, but also imaging tools and informatic solutions, developed for FL necessary for future preclinical studies.
format Online
Article
Text
id pubmed-8036410
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80364102021-04-12 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma Gava, Fabien Faria, Carla Gravelle, Pauline Valero, Juan G. Dobaño-López, Cèlia Morin, Renaud Norlund, Marine Gomes, Aurélie Lagarde, Jean-Michel Rossi, Cédric Bordenave, Julie Pieruccioni, Laetitia Rouquette, Jacques Matas-Céspedes, Alba Fournié, Jean-Jacques Ysebaert, Loïc Laurent, Camille Pérez-Galán, Patricia Bezombes, Christine Cancers (Basel) Article SIMPLE SUMMARY: Follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Although huge efforts have been made in the last 10 years, this pathology is still considered as incurable, leaving open the discovery and testing of new therapeutic targets requiring relevant preclinical models. Here, we report a realistic 3D model of t (14;18)-positive B-NHL cell culture (ultra-low attachment (ULA)-multicellular aggregates of lymphoma cells (MALC)), which monitored by state-of-the-art 2D and 3D imaging, allows more robust drug testing. ABSTRACT: Follicular lymphoma (FL) is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Great advances have been made to identify the most relevant targets for precision therapy. However, no relevant models for in vitro studies have been developed or characterized in depth. To this purpose, we generated a 3D cell model from t(14;18)-positive B-NHL cell lines cultured in ultra-low attachment 96-well plates. Morphological features and cell growth behavior were evaluated by classical microscopy (2D imaging) and response to treatment with different drugs was evaluated by a high-content analysis system to determine the robustness of the model. We show that the ultra-low attachment (ULA) method allows the development of regular, spherical and viable ULA-multicellular aggregates of lymphoma cells (MALC). However, discrepancies in the results obtained after 2D imaging analyses on drug-treated ULA-MALC prompted us to develop 3D imaging and specific analyses. We show by using light sheet microscopy and specifically developed 3D imaging algorithms that 3D imaging and dedicated analyses are necessary to characterize morphological properties of 3D models and drug effects. This study proposes a new method, but also imaging tools and informatic solutions, developed for FL necessary for future preclinical studies. MDPI 2021-03-24 /pmc/articles/PMC8036410/ /pubmed/33804934 http://dx.doi.org/10.3390/cancers13071490 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Gava, Fabien
Faria, Carla
Gravelle, Pauline
Valero, Juan G.
Dobaño-López, Cèlia
Morin, Renaud
Norlund, Marine
Gomes, Aurélie
Lagarde, Jean-Michel
Rossi, Cédric
Bordenave, Julie
Pieruccioni, Laetitia
Rouquette, Jacques
Matas-Céspedes, Alba
Fournié, Jean-Jacques
Ysebaert, Loïc
Laurent, Camille
Pérez-Galán, Patricia
Bezombes, Christine
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
title 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
title_full 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
title_fullStr 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
title_full_unstemmed 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
title_short 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
title_sort 3d model characterization by 2d and 3d imaging in t(14;18)-positive b-nhl: perspectives for in vitro drug screens in follicular lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036410/
https://www.ncbi.nlm.nih.gov/pubmed/33804934
http://dx.doi.org/10.3390/cancers13071490
work_keys_str_mv AT gavafabien 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT fariacarla 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT gravellepauline 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT valerojuang 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT dobanolopezcelia 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT morinrenaud 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT norlundmarine 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT gomesaurelie 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT lagardejeanmichel 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT rossicedric 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT bordenavejulie 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT pieruccionilaetitia 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT rouquettejacques 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT matascespedesalba 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT fourniejeanjacques 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT ysebaertloic 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT laurentcamille 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT perezgalanpatricia 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma
AT bezombeschristine 3dmodelcharacterizationby2dand3dimagingint1418positivebnhlperspectivesforinvitrodrugscreensinfollicularlymphoma